Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis

Authors not listed

Maastricht University Medical Center · 2022

Abstract

The goal of this observational longitudinal study is to investigates whether tear fluid is a non-invasive source of biomarkers for Alzheimer's disease. The main aim of the study is to evaluate diagnostic accuracy measures (sensitivity and specificity) of tear and retinal biomarkers to discriminate individuals with and without neurodegeneration. Tear fluid from participants will be collected non-invasively with Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes. Additionally, standard, ultra-wide field and cross-sectional retinal images will be obtained.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-10 MST

Cite this

APA
Anonymous. (2022). The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis. <em>Maastricht University Medical Center</em>. https://clinicaltrials.gov/study/NCT05655793
Vancouver
Anonymous. The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis. Maastricht University Medical Center. 2022.
BibTeX
@misc{anon2022TheTea, title = {The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis}, author = {Anonymous}, journal = {Maastricht University Medical Center}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings